Small Molecule Toxins Targeting Tumor Receptors

Author(s): Marcin Dyba, Nadya I. Tarasova, Christopher J. Michejda

Journal Name: Current Pharmaceutical Design

Volume 10 , Issue 19 , 2004

Become EABM
Become Reviewer
Call for Editor


Targeting toxic therapeutics to tumors through receptors over expressed on the surface of cancer cells can reduce systemic toxicity and increase the effectiveness of the targeted compounds. Small molecule targeted therapeutics have a number of advantages over toxic immunoconjugates including better tumor penetration, lack of neutralizing host immune response and superior flexibility in selection of drug components with optimal specificity, potency and stability in circulation. Three major components of the targeted drug, the toxic warhead, tumor-specific ligand and the linker can influence the properties of each other and thus have to be optimized for each system. All receptor-targeted drugs are delivered inside the cells through endocytosis and undergo processing liberating the toxins in endosomes and lysosomes. Common delivery route defines a number of general requirements for each drug component. The review addresses currently known possible receptor targets and their ligands along with toxins that have been used and that have a potential to be successfully applied in tumor targeting. Linkers that are stable in circulation, but efficiently cleaved in lysosomes constitute an essential component of receptor-targeted drugs and are evaluated in greater detail.

Keywords: peptide therapeutics, anti-cancer drugs, lysosomal cleavage, drug delivery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [2311 - 2334]
Pages: 24
DOI: 10.2174/1381612043384024
Price: $65

Article Metrics

PDF: 18